Overview
Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema
Status:
Completed
Completed
Trial end date:
2018-12-28
2018-12-28
Target enrollment:
0
0
Participant gender:
All
All
Summary
prospective study evaluating the impact of subthreshold micropulsed laser on the number of Aflibercept injections when used as an adjuvant therapy in eyes with diabetic macular edema.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Al Hadi HospitalTreatments:
Aflibercept
Criteria
Inclusion Criteria:- older than 18 years old
- diagnosed with DME with central macular thickness (CMT) more than 250 µm measured by
OCT
- best corrected visual acuity (BCVA) between 20/400 and 20/40.
Exclusion Criteria:
- patients with intra-ocular surgery as cataract surgery within 6 months
- prior intravitreal injection of any drug within the preceding 6 months
- panretinal photocoagulation (PRP) within the former 4 months.
- Patients with previous macular laser
- patients with vitreo-macular traction (VMT) syndrome
- severe glaucoma
- other retinal vascular diseases
- conditions that impede the OCT interpretation